<![CDATA[LFB S.A. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=22364>Thu, 23 Apr 2026 19:30:15 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Denis DELVAL is Appointed CEO of LFB SA]]>https://www.newswire.co.kr/newsRead.php?no=862027Fri, 22 Dec 2017 08:57:11 +0900<![CDATA[LFB S.A. Announced Today the Acceptance by U.S. Food and Drug Administration of the Filed Biologic License Application for Coagulation Factor VIIa Recombinant, (eptacog beta activated)]]>https://www.newswire.co.kr/newsRead.php?no=843177Mon, 09 Jan 2017 10:55:00 +0900<![CDATA[LFB S.A., 미국 식약청이 6일 응고인자 VIIa 재조합체에 대한 생물의약품 승인 신청서 수락 발표]]>https://www.newswire.co.kr/newsRead.php?no=843178Mon, 09 Jan 2017 10:55:00 +0900<![CDATA[Manufacturing Authorization of Gene Therapy Medicinal Products Granted to CELLforCURE, the LFB Group Subsidiary Specialized in Innovative Therapies]]>https://www.newswire.co.kr/newsRead.php?no=783030Fri, 13 Feb 2015 13:10:00 +0900<![CDATA[혁신 치료제 전문 LFB그룹 자회사 셀포큐어, 유전자 치료 의약품 제조 허가 취득]]>https://www.newswire.co.kr/newsRead.php?no=783032Fri, 13 Feb 2015 13:10:00 +0900<![CDATA[LFB S.A. Announces Achievement of Patient Enrollment Target for PerSept 1 Program for the Evaluation of Recombinant Factor Seven Efficacy by Prospective Clinical Trials]]>https://www.newswire.co.kr/newsRead.php?no=777804Thu, 18 Dec 2014 14:00:00 +0900<![CDATA[LFB S.A., 전향적 임상시험에 의한 제7혈액응고인자 유효성 평가를 위한 PERSEPT 1 프로그램의 환자 등록 목표치 달성]]>https://www.newswire.co.kr/newsRead.php?no=777806Thu, 18 Dec 2014 14:00:00 +0900<![CDATA[LFB SA Announces That First Patient Has Begun Treatment with New Coagulation Factor VIIa (Recombinant) in Global Phase 3 Clinical Trial in Hemophilia A and B with Inhibitors]]>https://www.newswire.co.kr/newsRead.php?no=750327Thu, 15 May 2014 13:40:00 +0900<![CDATA[LFB SA, 항체 형성된 A형 및 B형 혈우병에 대한 글로벌 임상실험 3단계에서 환자의 새로운 제7혈액응고인자(재조합) 치료 시작]]>https://www.newswire.co.kr/newsRead.php?no=750328Thu, 15 May 2014 13:40:00 +0900